Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (CSE: MDMA ) 0.2600 UNCHANGED Streaming Delayed Price Updated: 9:41 AM EST, Nov 13, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about MDMA PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA October 21, 2024 From PharmAla Biotech Via GlobeNewswire PharmAla Launches MDMA Clinical Trial Tool for Researchers August 22, 2024 From PharmAla Biotech Via GlobeNewswire PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002 August 09, 2024 From PharmAla Biotech Via GlobeNewswire Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale May 29, 2024 Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now! Via Benzinga Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia April 05, 2024 Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities From PharmAla Biotech Via GlobeNewswire Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office March 27, 2024 Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities From PharmAla Biotech Via GlobeNewswire Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office March 20, 2024 Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications From PharmAla Biotech Via GlobeNewswire Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme March 18, 2024 PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market From PharmAla Biotech Via GlobeNewswire PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing January 24, 2024 New ticker symbol goes into effect immediately From PharmAla Biotech Via GlobeNewswire PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance January 08, 2024 PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco From PharmAla Biotech Via GlobeNewswire PharmAla Begins Trading on OTCQB September 06, 2023 From PharmAla Biotech Via GlobeNewswire PharmAla Files Patent for Novel MDXX Molecule PharmAla-1 July 31, 2023 Patent Filing Follows Year of Preclinical Research, Academic Publication From PharmAla Biotech Via GlobeNewswire Life Science Investor Forum: Presentations Now Available for Online Viewing June 23, 2023 Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Life Science Investor Forum Agenda Announced for June 22nd June 20, 2023 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States June 09, 2023 From PharmAla Biotech Via GlobeNewswire PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health May 01, 2023 From PharmAla Biotech Via GlobeNewswire Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development February 06, 2023 From Revive Therapeutics Ltd. Via GlobeNewswire Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change February 03, 2023 PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today From PharmAla Biotech Via GlobeNewswire The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News January 27, 2023 Via ACCESSWIRE KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing December 16, 2022 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference December 13, 2022 Company invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation From Virtual Investor Conferences Via GlobeNewswire KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th December 13, 2022 Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com From Virtual Investor Conferences Via GlobeNewswire Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement November 16, 2022 PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers From PharmAla Biotech Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
